Gilead Sciences Inc. said Wednesday it would start late-stage studies of its experimental treatment for the coronavirus in March, an acceleration of its push to evaluate what it hopes could be the first medicine specifically approved to treat the respiratory disease.

Gilead said it would conduct two studies with a total of 1,000 patients across mainly Asian countries, as well as other nations with high numbers of diagnosed patients.

...